Updates in lethal prostate cancer in the PLCO trial
Principal Investigator
Name
Jonathan Shoag
Degrees
MD
Institution
Weill Cornell Medicine
Position Title
Assistant professor
About this CDAS Project
Study
PLCO
(Learn more about this study)
Project ID
PLCO-701
Initial CDAS Request Approval
Dec 21, 2020
Title
Updates in lethal prostate cancer in the PLCO trial
Summary
Survival characteristics of patients in the PLCO trial were well described at the time of initial data publication. Prostate cancer is distinct from lung, colorectal, and ovarian malignancies, however, in that the tumors generally progress slowly and several years can lapse between diagnosis and death. As a consequence, mortality data is more likely to evolve significantly over time and impact results of previously published studies. We hope to utilize updated survival data from patients enrolled in the PLCO trial to shed light on lethal prostate cancer in the screening arm of the PLCO trial. We plan to analyze demographic and oncologic data amongst patients in the screening arm in relation to prostate cancer mortality. A granular understanding of this cohort of patients better informs the underpinnings of why cancer screenings fail, and is important in the interpretation of the trial's various conclusions. We anticipate that updated survival data on these cohorts will strengthen previous findings and have the potential to reveal novel predictors of cancer-specific mortality.
Aims
-understand patterns of lethal prostate cancer in screened patients
-identify predictors and pre-disposing factors leading to death from prostate cancer in a screened population
-strengthen the conclusions of initial reports describing this unique cohort
Collaborators
N/a